Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
- Details
- Category: Novartis
Novartis has announced that it is adding to its diverse and deep immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology. The agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment.
Shire to combine with Baxalta, creating the global leader in rare diseases
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) and Baxalta Incorporated (NYSE: BXLT) announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta.
Pfizer expands R&D equity investment strategy to access early-stage scientific innovations
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has announced an expansion of its Research & Development (R&D) investment strategy to include early-stage companies on the leading edge of scientific innovation, providing them with both equity and access to resources for research in promising areas aligned with Pfizer's core interests.
AstraZeneca and Moderna Therapeutics announce new collaboration to co-develop and co-commercialise immuno-oncology mRNA therapeutics™
- Details
- Category: AstraZeneca
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics announced a new collaboration to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers.
Merck Acquires IOmet Pharma and expands immuno-oncology development program
- Details
- Category: Merck
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has acquired IOmet, a privately-held UK-based drug discovery company focused on the development of innovative medicines for the treatment of cancer, with a particular emphasis on the fields of cancer immunotherapy and cancer metabolism.
Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries
- Details
- Category: Bayer
Bayer will halve the price of its contraceptive implant Jadelle until 2023 for women living in poor countries around the world. According to the Reproductive Health Supply Coalition the demand for implants is increasing continuously in these countries.
Sanofi Genzyme announces recipients of Patient Advocacy Leadership (PAL) awards
- Details
- Category: Genzyme
Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the recipients of the fifth annual Patient Advocacy Leadership (PAL) awards. The global grant program supports projects by non-profit organizations that serve patients living with lysosomal storage disorders (LSDs), a group of rare, inherited disorders that can cause progressive and debilitating health problems.
More Pharma News ...
- Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
- Merck KGaA, Darmstadt, Germany, Pfizer and Syndax announce collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer
- Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
- Bayer and CRISPR Therapeutics AG join forces to discover, develop and commercialize potential cures for serious genetic diseases
- Bristol-Myers Squibb to sell its HIV R&D portfolio to ViiV Healthcare
- AstraZeneca enhances long-term growth through oncology investment in Acerta Pharma
- Takeda announces sale of respiratory portfolio to AstraZeneca